Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come
- PMID: 16327812
- DOI: 10.1038/sj.bmt.1705242
Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come
Abstract
Relapses after autologous stem cell transplants for hematopoietic malignancies are frequent and post-transplant infections continue to cause significant post-transplant morbidity and even mortality. The post-transplant period is typically characterized by low lymphocyte counts and impaired immune cell function. Early restoration of immune function may contribute to better disease control and enhance protection from infections. Indeed the attainment of a 'minimal residual disease' status following high-dose therapy makes the early post-transplant period ideal for the introduction of antitumor immunotherapy. Attempts to generate immunity against tumor and microbial antigens after autotransplantation have included vaccinations, T cell infusions (both resting and activated) and combinations of vaccinations and adoptive T cell infusions. One successful strategy for generating robust immune responses against microbial antigens was the combination of pre and post-transplant immunizations along with an early (post-transplant) infusion of in vivo vaccine-primed and ex vivo co-stimulated autologous T cells. Whether this or similar strategies will lead to the generation of effective antitumor immunity is unknown. The lessons gained from efforts to rebuild immune system function in the setting of autotransplantation may also be applicable to the problem of restoring immunity in other immunodeficient groups such as patients with cancer or HIV disease and the elderly.
Similar articles
-
High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.Neuropediatrics. 2008 Jun;39(3):151-6. doi: 10.1055/s-0028-1093333. Epub 2008 Nov 7. Neuropediatrics. 2008. PMID: 18991194 Clinical Trial.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Enhancing immune responses for cancer therapy.Cell Mol Immunol. 2007 Jun;4(3):173-84. Cell Mol Immunol. 2007. PMID: 17601371 Review.
-
Autologous white blood cell transfusion: toward a younger immunity.Hum Immunol. 2007 Oct;68(10):805-12. doi: 10.1016/j.humimm.2007.07.004. Epub 2007 Aug 16. Hum Immunol. 2007. PMID: 17961768 Review.
-
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.Clin Cancer Res. 2007 Mar 15;13(6):1883-91. doi: 10.1158/1078-0432.CCR-06-2083. Clin Cancer Res. 2007. PMID: 17363545
Cited by
-
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.Clin Cancer Res. 2009 Jul 1;15(13):4499-507. doi: 10.1158/1078-0432.CCR-09-0418. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509133 Free PMC article. Clinical Trial.
-
Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients.Mycopathologia. 2009 Dec;168(6):271-82. doi: 10.1007/s11046-009-9181-0. Epub 2009 Jan 21. Mycopathologia. 2009. PMID: 19156534 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical